Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region.
Journal
Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780
Informations de publication
Date de publication:
23 Jun 2023
23 Jun 2023
Historique:
medline:
26
6
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
epublish
Résumé
Post-COVID conditions are characterised by persistent symptoms that negatively impact quality of life after SARS-CoV-2 diagnosis. While post-COVID risk factors and symptoms have been extensively described in localised regions, especially in the global north, post-COVID conditions remain poorly understood globally. The global, observational cohort study HVTN 405/HPTN 1901 characterises the convalescent course of SARS-CoV-2 infection among adults in North and South America and Africa. We categorised the cohort by infection severity (asymptomatic, symptomatic, no oxygen requirement (NOR), non-invasive oxygen requirement (NIOR), invasive oxygen requirement (IOR)). We applied a regression model to assess correlations of demographics, co-morbidities, disease severity, and concomitant medications with COVID-19 symptom persistence and duration across global regions. We enrolled 759 participants from Botswana, Malawi, South Africa, Zambia, Zimbabwe, Peru, and the USA a median of 51 (interquartile range (IQR) = 35-66) days post-diagnosis, from May 2020 to March 2021. 53.8% were female, 69.8% were 18-55 years old (median (md) = 44 years old, IQR = 33-58). Comorbidities included obesity (42.8%), hypertension (24%), diabetes (14%), human immunodeficiency virus (HIV) infection (11.6%) and lung disease (7.5%). 76.2% were symptomatic (NOR = 47.4%; NIOR = 22.9%; IOR = 5.8%). Median COVID-19 duration among symptomatic participants was 20 days (IQR = 11-35); 43.4% reported symptoms after COVID-19 resolution, 33.6% reported symptoms ≥30 days, 9.9% reported symptoms ≥60 days. Symptom duration correlated with disease severity (P < 0.001, NIOR vs NOR; P = 0.003, IOR vs NOR), lung disease (P = 0.001), race (P < 0.05, non-Hispanic Black vs White), and global region (P < 0.001). Prolonged viral shedding correlated with persistent abdominal pain (odds ratio (OR) = 5.51, P < 0.05) and persistent diarrhoea (OR = 6.64, P < 0.01). Post-COVID duration varied with infection severity, race, lung disease, and region. Better understanding post-COVID conditions, including regionally-diverse symptom profiles, may improve clinical assessment and management globally. Clinicaltrials.gov (#NCT04403880).
Sections du résumé
Background
UNASSIGNED
Post-COVID conditions are characterised by persistent symptoms that negatively impact quality of life after SARS-CoV-2 diagnosis. While post-COVID risk factors and symptoms have been extensively described in localised regions, especially in the global north, post-COVID conditions remain poorly understood globally. The global, observational cohort study HVTN 405/HPTN 1901 characterises the convalescent course of SARS-CoV-2 infection among adults in North and South America and Africa.
Methods
UNASSIGNED
We categorised the cohort by infection severity (asymptomatic, symptomatic, no oxygen requirement (NOR), non-invasive oxygen requirement (NIOR), invasive oxygen requirement (IOR)). We applied a regression model to assess correlations of demographics, co-morbidities, disease severity, and concomitant medications with COVID-19 symptom persistence and duration across global regions.
Results
UNASSIGNED
We enrolled 759 participants from Botswana, Malawi, South Africa, Zambia, Zimbabwe, Peru, and the USA a median of 51 (interquartile range (IQR) = 35-66) days post-diagnosis, from May 2020 to March 2021. 53.8% were female, 69.8% were 18-55 years old (median (md) = 44 years old, IQR = 33-58). Comorbidities included obesity (42.8%), hypertension (24%), diabetes (14%), human immunodeficiency virus (HIV) infection (11.6%) and lung disease (7.5%). 76.2% were symptomatic (NOR = 47.4%; NIOR = 22.9%; IOR = 5.8%). Median COVID-19 duration among symptomatic participants was 20 days (IQR = 11-35); 43.4% reported symptoms after COVID-19 resolution, 33.6% reported symptoms ≥30 days, 9.9% reported symptoms ≥60 days. Symptom duration correlated with disease severity (P < 0.001, NIOR vs NOR; P = 0.003, IOR vs NOR), lung disease (P = 0.001), race (P < 0.05, non-Hispanic Black vs White), and global region (P < 0.001). Prolonged viral shedding correlated with persistent abdominal pain (odds ratio (OR) = 5.51, P < 0.05) and persistent diarrhoea (OR = 6.64, P < 0.01).
Conclusions
UNASSIGNED
Post-COVID duration varied with infection severity, race, lung disease, and region. Better understanding post-COVID conditions, including regionally-diverse symptom profiles, may improve clinical assessment and management globally.
Registration
UNASSIGNED
Clinicaltrials.gov (#NCT04403880).
Identifiants
pubmed: 37352144
doi: 10.7189/jogh.13.06020
pmc: PMC10289480
doi:
Banques de données
ClinicalTrials.gov
['NCT04403880']
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
06020Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI069423
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069470
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069470
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068614
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068635
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States
Informations de copyright
Copyright © 2023 by the Journal of Global Health. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and declare the following activities and relationships: PG reports funding from HVTN, consulting fees from Johnson & Johnson and DSMB activities. The other authors declare no conflicts of interest: KG, CK, JH, LP, MT, PH, RD, JGC, JM, LC, MJ, SL, VK, JH, MDM, SK, DT, NE, AT, RM.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
PLoS One. 2021 May 3;16(5):e0250602
pubmed: 33939733
Lancet Glob Health. 2022 Sep;10(9):e1247-e1256
pubmed: 35961348
Depress Anxiety. 2019 Jan;36(1):8-17
pubmed: 30188598
Int J Infect Dis. 2022 Sep;122:1044-1051
pubmed: 35908724
Sci Rep. 2022 Apr 20;12(1):6496
pubmed: 35444221
BMC Infect Dis. 2022 Feb 8;22(1):133
pubmed: 35135496
AIDS Care. 2018 Jun;30(6):774-783
pubmed: 29353489
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Int J Clin Pract. 2021 Oct;75(10):e14357
pubmed: 33977626
Pan Afr Med J. 2021 Jan 20;38:65
pubmed: 33889231
Crit Care. 2017 Dec 5;21(1):296
pubmed: 29208005
Stroke. 2021 May;52(5):e117-e130
pubmed: 33878892
BMC Geriatr. 2021 May 19;21(1):321
pubmed: 34011269
Stat Med. 2002 Aug 30;21(16):2409-19
pubmed: 12210625
BMC Infect Dis. 2021 Mar 25;21(1):304
pubmed: 33765941
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Lancet Glob Health. 2020 Aug;8(8):e1018-e1026
pubmed: 32622400
World J Gastroenterol. 2020 May 21;26(19):2323-2332
pubmed: 32476796
Int J Environ Res Public Health. 2022 May 13;19(10):
pubmed: 35627472
Rev Neurosci. 2021 Jan 13;32(3):351-361
pubmed: 33618441
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Int J Environ Res Public Health. 2022 Jan 04;19(1):
pubmed: 35010786
Clin Microbiol Infect. 2022 May;28(5):657-666
pubmed: 35124265
Clin Infect Dis. 2023 Feb 8;76(3):e487-e490
pubmed: 36052466
Front Public Health. 2022 Mar 31;10:856137
pubmed: 35433600
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34580069
Lancet. 2022 Jun 18;399(10343):2263-2264
pubmed: 35717982
J Infect Dis. 2022 Nov 1;226(9):1593-1607
pubmed: 35429399
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Sci Rep. 2021 May 7;11(1):9784
pubmed: 33963250
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
Biostatistics. 2014 Apr;15(2):222-33
pubmed: 24292992
Dermatol Ther. 2021 Mar;34(2):e14788
pubmed: 33481314
Int J Infect Dis. 2021 Jan;102:577-583
pubmed: 33176202
Front Med (Lausanne). 2021 Jul 15;8:667623
pubmed: 34336881
Infection. 2022 Oct;50(5):1067-1109
pubmed: 35750943
J Stroke Cerebrovasc Dis. 2020 Dec;29(12):105379
pubmed: 33254369
Mayo Clin Proc. 2020 Aug;95(8):1632-1648
pubmed: 32753138
Am J Infect Control. 2021 Feb;49(2):238-246
pubmed: 32659414
J Med Virol. 2020 Oct;92(10):1902-1914
pubmed: 32293716
Curr Opin Pharmacol. 2022 Apr;63:102203
pubmed: 35255454
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Sci Rep. 2021 Aug 9;11(1):16144
pubmed: 34373540
Emerg Infect Dis. 2022 Mar;28(3):730-733
pubmed: 35133956
Lancet. 2020 Dec 12;396(10266):1861
pubmed: 33308453